Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is based in Paris, France. Show more

60 rue de Wattignies, Paris, 75012, France

https://www.nanobiotix.com

Biotechnology

Healthcare

Start AI Chat

Market Cap

1.205B

52 Wk Range

$2.95 - $30.35

Previous Close

$24.90

Open

$25.50

Volume

14,264

Day Range

$25.35 - $25.74

Enterprise Value

982.3M

Cash

28.82M

Avg Qtr Burn

N/A

Insider Ownership

0.00%

Institutional Own.

11.82%

Qtr Updated

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
NBTXR3 +/- Cetuximab Details Head and neck cancer	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
JNJ-1900 (NBTXR3) Details Non-small cell lung carcinoma, Cancer	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
RT + NBTXR3 + Chemotherapy Details Esophageal cancer	Phase 1/2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
RT + NBTXR3 Details Cancer, Pancreatic cancer	Phase 1b Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
JNJ-1900 (NBTXR3) + Anti-PD-1 Details Head and neck cancer, Cancer, Non-small cell lung carcinoma, Solid tumor/s	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
RT + NBTXR3 Details Cancer, Non-small cell lung carcinoma	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
JNJ-1900 (NBTXR3) Details Pancreatic Cancer	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.